stockrowRepligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
Follow RGEN
Alert me
Repligen Corporation (RGEN) Return on invested capital
Repligen Corporation's return on invested capital over the twelve months to 30 September 2026 was 0.64%, down 1.2 percentage points from fiscal 2025 (1.83%). Over the past ten years it has ranged from −1.26% (fiscal 2024) to 16.9% (fiscal 2015); the current reading is higher than 36% of that period. That is above the Medical Instruments & Supplies industry median of 0.13% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 1.83% | 3.09 |
| FY2024 | −1.26% | (2.92) |
| FY2023 | 1.66% | (6.59) |
| FY2022 | 8.25% | 1.30 |
| FY2021 | 6.95% | 2.92 |
| FY2020 | 4.03% | 1.06 |
| FY2019 | 2.97% | (0.12) |
| FY2018 | 3.09% | 1.40 |
| FY2017 | 1.69% | (6.48) |
| FY2016 | 8.17% | (8.71) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ALGN Align Technology, Inc. compare | 12.3% |
| ATR AptarGroup, Inc. compare | 7.83% |
| AVTR Avantor, Inc. compare | 3.36% |
| COO The Cooper Companies, Inc. compare | 3.17% |
| BLCO Bausch + Lomb Corporation compare | 2.16% |
| RGEN Repligen Corporation | 0.64% |
| TFX Teleflex Incorporated compare | 0.51% |
| SOLV Solventum Corporation compare | 0.00% |
| BAX Baxter International Inc. compare | −1.05% |
| Medical Instruments & Supplies industry median | 0.13% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on RGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement